EMEA Liquid Biopsy Market Share Analysis by Key Companies & Geography

Executive Summery

This report presents a detailed overview of the EMEA Liquid Biopsy Market, highlighting key insights into its market size, share, and growth during the forecast period, i.e., 2023-28. It explores emerging trends, competitive dynamics, and the core drivers reshaping the industry. Backed by solid data and expert analysis, the study offers segment-wise insights and reliable forecasts to guide strategic decisions. With comprehensive market analysis and forward-looking perspectives, this report serves as a practical tool for stakeholders navigating change. Whether you're an investor, policymaker, or business leader, this research helps you stay ahead in the fast-evolving EMEA Liquid Biopsy industry landscape.

In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.

Download your free sample PDF of the report– https://www.marknteladvisors.com/query/request-sample/emea-liquid-biopsy-market.html

EMEA Liquid Biopsy Market Statistics and Key Highlights

The EMEA Liquid Biopsy Market is projected to grow at a CAGR of around 13.98% during the forecast period, 2023-28.

EMEA Liquid Biopsy market shows steady growth
Market size expanding due to rising industry demand
Competitive landscape driven by tech and innovation
Detailed segment-wise and geography wise share analysis
Forecast reveals strong trends shaping future outlook

Key Player- Emerging EMEA Liquid Biopsy Companies

Thermofisher Scientific
Hoffmann-La Roche Ltd
Sysmex Corporation
Qiagen N.V.
Guardant Health
Bio Rad
Neo Genomics
Epigenomics
Menarini-Silicon Biosystems
Agena Bioscience Inc.
Silicon Biosystems
Pathway Genomics Corporation
Others (Myraid Genetics, Illumina Inc.,etc)

Access Full Market Insights & Key Statistics! https://www.marknteladvisors.com/research-library/emea-liquid-biopsy-market.html

Use your official business email to connect with our team and enjoy full access with priority support.

Key Driver:

Prevalence in the Number of Cancer Patients Would Generate the Demand for Liquid Biopsy – Cancer has been a chronic disease over the past years & would continue to ascend in the forecasting year as well, owing to the increasingly sedentary lifestyle, smoking, and drinking habit of the individual, which would require better diagnostic facilities, treatment, and care for the patients. The continuous boost in the number of cancer patients emphasizes the need for accurate & convenient diagnostic systems for early cancer detection. Consequently, with the rising number of cancer patients, especially across Turkey, France, Denmark, etc., the usage of Liquid Biopsy is also uplifting. The advantages of liquid biopsy, like lower cost, early prognosis, therapy monitoring, etc., have further enhanced their adoption over conventional diagnostic methods to detect urothelial carcinoma, non-urological cancers, and other blood cancers.

The use of liquid biopsy has also been upscale to determine the best treatments for cancer patients, especially lung & prostate cancer, in which the patient receives specific targeted drugs. Hence, the improved investments by government organizations & pharmaceutical companies to escalate the research & development of new cancer treatments are anticipated to augment the growth of the EMEA Liquid Biopsy Market during the forecasted period.

Looking for Global, Regional or country-specific reports on this market?

Visit our website or simply fill out the inquiry form, and our team will reach out with customized insights and support - https://www.marknteladvisors.com/query/request-customization/emea-liquid-biopsy-market.html

EMEA Liquid Biopsy Market Segmentation

By Product and Services

Equipment
Assay Kits
Services

By Circulating Biomarker

Circulating Tumour Cell (CTC)
Circulating Tumour DNA (ctDNA)
Cell Free DNA (cfDNA)
Extracellular Vesicle (EVS)

By Technology

Multi gene analysis by Next Generation Sequencing (NGS)
Single gene analysis by Polymer chase reaction (PCR)

By Sample Type

Blood
Urine
Others (Cerebrospinal Fluid, Plasma, Saliva, etc.)

Blood Sample-based Testing dominated the EMEA Liquid Biopsy Market during the historical years, as it is highly preferred by cancer patients owing to its least invasive nature & reduced risk of incision into the body.

By Application

By Cancer Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma cancer
- Others (Pancreatic, Liver, etc.)
By Non Cancer Application
- Non Invasive Parental Testing
- Organ Transplantation
- Infectious Diseases
By Clinical Application
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring

By End User

Hospital and Physician laboratories
Reference Laboratories
Academic & Research Centre

By Country

Germany
The UK
France
Italy
Spain
Saudi Arabia
The UAE
Egypt
South Africa
Rest of Europe Middle East & Africa

Germany is expected to account for the majority of market share during the forecast period 2023-28, as the country has the highest adoption rate of liquid biopsy due to various healthcare companies such as Roche, Qiagen N.V.

Reasons to Buy This Report

Gain comprehensive insights into current market trends and dynamics.
Equip your business with data-driven strategies for informed decisions.
Identify lucrative market opportunities and strategic growth areas.
Analyze competitors to enhance your positioning in the market landscape.
Understand geographical trends across diverse markets for better expansion strategies.

Other reports

About US:

MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.

Contact Us:

MarkNtel Advisors LLP

Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511

Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India

For Sales Enquiries: sales@marknteladvisors.com